Recursion Pharmaceuticals Highlights AI Platform, Roche Progress and Pipeline UpdatesMarket Beat·11 hours agoRXRX-0.38%SNY+1.29%
MAIA Biotechnology 6M 2026: Net loss $(14.31M), Diluted EPS $(0.27) — 10-Q SummaryTradingView·Aug 10 at 08:11 AMMAIA-1.07%REGN+0.81%
ChemoMetec, Roche Diagnostics partner to develop connectivity kit for bioprocess analyzersPUBT·Aug 10 at 05:32 AMRHHBY+0.59%
Prothena publishes corporate overview presentation on protein-dysregulation drug pipelinePUBT·Aug 6 at 04:33 PMPRTA+1.35%NVO-0.54%
Prothena Q2 FY26 net loss narrows to $18.6 million; revenue drops to $1 millionPUBT·Aug 6 at 03:22 PMPRTA+1.35%RHHBY+0.59%
Evexta Bio and Roche plan Phase Ib trial of rupitasertib with giredestrantWorldPharmaceuticals·Aug 5 at 05:34 AMRHHBY+0.59%
Recursion Q2 net loss narrows to $131.01 million; revenue drops to $7.67 millionPUBT·Aug 5 at 05:31 AMRXRX-0.38%RHHBY+0.59%
Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast CancerUnusual Whales·Aug 4 at 02:02 AMRHHBY+0.59%
IDEAYA Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update | IDYA Stock NewsStockTitan·Aug 3 at 09:00 PMIDYA+1.03%RHHBY+0.59%
Genprex Announces Collaboration with Roche Diagnostics for Biomarker Assay Validation Studies | GNPX Stock NewsStockTitan·Aug 2 at 10:00 PMGNPX+7.52%RHHBY+0.59%
12:00 ETADLM announces 2026 Top Corporate Supporter Award recipients and thanks them for their essential backingprnewswire·Jul 28 at 11:01 AMDHR-0.53%ABT-0.94%
Roche (SWX:ROG) Stock Margin Expansion To 19.6% Tests Bullish Earnings NarrativesSimplywall·Jul 24 at 04:17 PMRHHBY+0.59%
CHMP recommends EU approval of Roche’s Susvimo, the first continuous delivery treatment for neovascular age-related macular degeneration (nAMD) | RHHBY Stock NewsStockTitan·Jul 23 at 09:15 PMRHHBY+0.59%
